Elicera Therapeutics

SCRM is Sweden's largest cancer research meeting, held every other year, where prominent international researchers are also invited. At SCRM2025, leading representatives from academia, healthcare, and industry will gather to exchange knowledge, present new research findings, and foster collaboration. The goal is to strengthen Sweden's cancer research ecosystem and create the conditions for joint efforts that can lead to improved treatments and a deeper understanding of cancer.

Magnus Essand, one of the co-founders of Elicera Therapeutics and Professor of Gene Therapy at Uppsala University, will participate as a speaker at SCRM2025. His presentation, titled "Novel cell and gene therapies for the treatment of cancer - The Uppsala experience", will highlight the company's progress in developing novel cell and gene therapies for cancer treatment.

During his talk, Professor Essand will present Elicera Therapeutics' CAR T-cell program and the company's proprietary platform technology, iTANK, which is used to arm CAR T-cells to trigger a broad immune activation against cancer. He will also present preliminary efficacy data from cohort 1 of the ongoing CARMA study, which evaluates the safety and efficacy of ELC-301 - the company's iTANK-armed CAR T-cell therapy targeting B-cell lymphoma.

In light of this, Elicera has decided not to present the cohort 1 data at the ISCT conference, in order to generate greater impact at SCRM2025. This decision also enables the inclusion of data from a longer follow-up period, which is expected to provide a more informative and valuable data set.